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Abstract
A comprehensive description of genomic alterations in lung squamous cell carcinoma (lung
SqCC) has recently been reported, enabling the identification of genomic events that contribute to
the oncogenesis of this disease. In lung SqCC, one of the most frequently altered receptor tyrosine
kinase families is the fibroblast growth factor receptor (FGFR) family, with amplification or
mutation observed in all four family members. Here, we describe the oncogenic nature of
mutations observed in FGFR2 and FGFR3, which are each observed in 3% of samples, for a
mutation rate of 6% across both genes. Using cell culture and xenograft models, we show that
several of these mutations drive cellular transformation. Transformation can be reversed by small
molecule FGFR inhibitors currently being developed for clinical use. We also show that mutations
in the extracellular domains of FGFR2 lead to constitutive FGFR dimerization. Additionally, we
report a patient with an FGFR2-mutated oral squamous cell carcinoma who responded to the
multi-targeted tyrosine kinase inhibitor pazopanib. These findings provide new insights into
driving oncogenic events in a subset of lung squamous cancers, and recommend future clinical
studies with FGFR inhibitors in patients with lung and head and neck SqCC.
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Introduction
Two goals of comprehensive next-generation sequencing of cancers are to discover novel,
targetable somatic alterations, and to identify new targets for which therapies already exist.
Genome-scale analyses of tumors representing many cancer types have recently been
completed (1–6), enabling discoveries consistent with both goals.
Historically, targetable oncogenic alterations in cancer were discovered on an individual
gene basis. This was the case for cancer-causing alterations observed in several tyrosine
kinases, including EGFR and ALK in lung adenocarcinoma (7–9), FGFR2 in endometrial
carcinoma (10, 11), and FGFR3 in urothelial carcinoma (12). These studies and others have
led to demonstrations of the successful application of targeted therapeutic agents and their
superiority to conventional chemotherapy (13, 14).
Lung squamous cell carcinoma (lung SqCC) is a prevalent and deadly disease for which no
targeted therapies are approved. Recent data reported by The Cancer Genome Atlas (TCGA)
lung SqCC project (4) demonstrated that the Fibroblast Growth Factor Receptor (FGFR)
tyrosine kinases are one of the most frequently altered kinase families in this disease.
Amplification of FGFR1 was observed, in agreement with prior reports (15, 16).
Furthermore, mutations in FGFR2 and FGFR3 were reported. While the frequency of these
mutations did not reach statistical significance at the cohort size examined by TCGA,
several features including recurrence, prior observation in other cancer types and congenital
syndromes, and lack of other dominant oncogenic alterations in tumors with FGFR
mutations, suggested they might be driving, targetable events in a subset of patients
presenting with this disease.
Germline mutations in the FGFR tyrosine kinase family were first described in craniofacial
and skeletal syndromes (17). Somatic point mutations identical to those germline events
have also been observed in malignancies (18). The FGFR family is made up of four active
members that each contain an extracellular domain (ECD) and a cytoplasmic kinase domain.
Activation is stimulated by binding fibroblast growth factor (FGF) and heparan sulfate
proteoglycan (HSPG) in the ECD, and subsequent dimerization of two receptor-ligand
complexes, leading to transphosphorylation of the kinase domains. This leads to
phosphorylation of binding partner FRS2 and downstream activation of Ras/MAPK and
PI3K/AKT pathways (19).
The FGF family is made up of more than 20 members, all of which retain specificities for
both different FGFR family members and different isoforms of each receptor (20). In
addition, tissue types vary in which receptors, isoforms, and ligands are expressed, adding
further levels of complexity to the system. Dysregulation can lead to oncogenesis, as has
been shown with altered expression of receptors (15, 16, 21), altered isoform expression (22,
23), and altered ligand specificity (24) driven by somatic genomic events.
Aberrant FGFR signaling has been implicated in the development of several cancer types. In
addition to lung SqCC, FGFR1 amplification is observed in 10% of breast cancers (21).
Point mutations in FGFR2 are observed in 12% of endometrial carcinomas (10) and
mutations in FGFR3 are observed in more than 30% of urothelial carcinomas (12). Cell lines
harboring these events have demonstrated sensitivity to inhibition by FGFR small molecule
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inhibitors, and clinical trials are now testing FGFR inhibitors in patients harboring somatic
events in FGFRs (18).
Here, we characterize FGFR2 and FGFR3 mutations observed in lung SqCC and
demonstrate the oncogenic potential of these mutations using models of transformation and
dependency. We demonstrate that cells harboring these mutations are sensitive to inhibition
by several FGFR and multi-kinase inhibitors. In addition, we report a case of a patient with
an FGFR2-mutated oral squamous cell carcinoma, who responded to pazopanib, an inhibitor
of multiple tyrosine kinases including the FGFR family. Together, these data identify a
promising new therapeutic target for patients with lung SqCC and other squamous epithelial
tumors.
Methods
Patient samples and genomic analysis
We manually reviewed FGFR2 and FGFR3 exome sequencing data generated by the TCGA
research network. Additionally, we queried publically available sequencing data generated
from 18 samples that were excluded from the initial TCGA report. All data were de-
identified and obtained in accordance with patient protection standards set by the TCGA and
were obtained from the TCGA Data Portal.
For the individual with a clinical response to pazopanib, total RNA was extracted using the
AllPrep DNA/RNA Mini Kit (Qiagen #80204). Poly-adenylated mRNA was enriched using
the Ambion MicroPoly(A)Purist kit starting from 30 μg of total RNA as an input according
to the manufacturer’s protocol.
Illumina transcriptome sequencing libraries were prepared as previously described (25) from
mRNA and from total RNA and were subjected to 76 bp paired-end sequencing on a single
lane of an Illumina GAIIx sequencer. Sequencing reads were first aligned to all curated
protein-coding transcripts and were mapped back to reference human genome, hg18 as
previously described (25). Potential mutations were called using the Unified genotyper from
the GATK tool (26).
This individual was consented for the analysis according to Institutional Protocol 94138 at
the Dana-Farber Cancer Institute. The FGFR2 P253R mutation was found in both the total
RNA-seq data and mRNA-seq data, and it was confirmed from genomic DNA by Sanger
sequencing in a CLIA-certified laboratory.
Cell lines, antibodies, ligands, and inhibitors
NIH-3T3 cells and Ba/F3 cells were obtained from the American Type Culture Collection
and maintained as described previously (10, 20). Antibodies against FGFR2 (C-8) and FRS2
(H-91) were purchased from Santa Cruz Biotechnology, Inc. Antibodies against FGFR3
(C51F2), p-FGFR, p-FRS2 (Y436), AKT (C67E7), p-AKT (T308, 244F9), Erk 1/2 (137F5),
p-Erk 1/2 (E10), and beta-actin (8H10D10) were obtained from Cell Signaling Technology,
Inc.
For FGFR stimulation experiments, the FGF1 ligand was obtained from Abcam. FGF7 and
FGF9 were obtained from Life Technologies. Interleukin-3 (IL-3) was purchased from
VWR and heparin from StemCell Technologies, Inc.
Ponatinib (AP24534), dovitinib (TKI258), and cediranib (AZD2171) were obtained from
Selleck Chemicals. Brivanib alaninate (BMS-582664) was obtained from Fischer Scientific.
Pazopanib (GW786034) was obtained from Axon Medchem. AZD4547 was obtained from
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Active Biochem. E7080 was obtained from American Custom Chemicals Corporation.
BGJ398 was a gift from Novartis Pharmaceuticals Corporation (Basel, CH).
Mutagenesis and cellular transfection and infection
Mutagenesis primers developed for each mutation were generated using the Agilent
QuikChange Primer Design tool. FGFR2 isoforms IIIb and IIIc, and FGFR3 isoform IIIc
were cloned into pDONR223 and mutated by site-directed mutagenesis with the
QuikChange Lightning Site-Directed Mutagenesis Kit from Agilent Technologies.
Sequence-verified constructs were cloned into pBabe-puro and transfected into HEK-293T
cells with Fugene-6 (Promega) as described previously (10). NIH-3T3 and Ba/F3 cells were
infected with the resulting virus and after two days and cells were selected with 2 μg/mL
puromycin.
Western blot analysis and visualization of unreduced dimers
Cells were lysed in buffer containing 0.5% NP-40, 50 mM Tris pH 8, 150 mM MgCl2, and
phosphatase and protease inhibitors, and proteins were separated by SDS/PAGE and
transferred to nitrocellulose membranes via the iBlot dry transfer system (Invitrogen).
Antibody binding was detected using the LI-COR Odyssey IR imaging system (LI-COR
Biosciences).
To visualize receptor dimers formed by extracellular domain mutations to cysteine residues,
NIH-3T3 cells expressing the appropriate mutations were serum starved for eight hours in
the presence of PBS or FGF1 and heparin, washed with PBS containing 10mM
iodoacetamide, and lysed in lysis buffer containing 1% Triton, 10% glycerol, 50mM Tris pH
7.4, and 10 mM iodoacetamide. Two 100 μg aliquots of each protein sample were prepared,
one with reducing agent and one without. Electrophoresis was performed using 4–12% Tris-
glycine SDS/PAGE gels (Invitrogen)
To confirm loss of phosphorylation of relevant kinases in the presence of inhibitor, NIH-3T3
cells expressing mutated FGFR2 or FGFR3 were washed with PBS, serum starved for four
hours in the presence of indicated concentrations of inhibitor, and ligand stimulated with
FGF1 for 30 minutes before lysis.
Soft agar colony formation assays
Two mL of 0.5% Select agar (Gibco) and media were plated to each well of a non-tissue
culture-treated 6-well plate and allowed to solidify. 5×104 cells were suspended in 330 μL
media and mixed with 770 μL 0.5% Select agar and media and plated onto the solidified
bottom layer in triplicate. Plates were incubated for three weeks, photographed using
QuickCapture (Logitech), and quantified via ImageJ for colony formation. Statistical
comparison was performed using the Student’s t-test.
To evaluate the effect of clinical inhibitors on soft agar colony formation, the above protocol
was performed with the following alteration: 5×104 cells were suspended in 330 μL media
plus relevant inhibitor prior to addition of 0.5% agar solution and plating.
Xenograft studies
All animal experiments were performed according to institutional guidelines regarding
animal safety. Immuno-compromised mice were injected with NIH-3T3 cells stably
expressing exogenous FGFR2-IIIb WT, W290C, S320C or K660N mutant isoforms.
Cohorts of 7 mice were injected at 3 sites for each cell type with two million cells per site,
and mice were observed until tumor volume reached 200–300 mm3. Mice were then treated
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with BGJ-398 at 15 mg/kg or vehicle (PEG-300) control daily for 2 weeks, and tumor size
was measured during the treatment period.
Ba/F3 dependency and inhibitor studies
Ba/F3 cells expressing each mutation construct were selected in media containing IL-3 and
puromycin. To establish cells dependent on FGFR signaling, three million cells were
washed twice with PBS and seeded into 2 mL of media containing FGF7 (for FGFR2 IIIb)
or FGF9 (for FGFR2 IIIc) and heparin. These cells were maintained until IL-3 independent
cells emerged. 5000 FGFR-dependent cells per well were seeded into 96-well plates in 100
μL media containing FGF and heparin. 10 μL drug was added in quadruplicate for final
concentrations of 0.3nM-10 μM in half logs, with two DMSO controls, and incubated for
three or four days. 50 μL Cell Titer Glo (Promega) was added to each well and
luminescence was measured on the SpectroMax 5 imager. Percent survival compared to
DMSO controls was calculated and plotted in Prism (GraphPad Software, Inc).
Results
FGFR2 and FGFR3 are recurrently mutated in lung squamous cell carcinoma
We analyzed whole-exome sequencing data generated by The Cancer Genome Atlas (4), for
mutations in the FGFR2 and FGFR3 genes. We identified 5 FGFR2 and 6 FGFR3 mutations
in analysis of exome sequencing data of 178 tumor/normal pairs, as well as an FGFR2
K660N mutation in a sample that was excluded from the TCGA report due to poor RNA
quality (TCGA-21-1083), for a total of 12 mutations.
Patients in the reported TCGA cohort with FGFR mutations (n=10, as one subject had two
FGFR mutations) ranged from 58 to 81 years old with a median age of 73. All patients were
current or former smokers with a pack year history of 9 to 63 pack years (median 49).
Tumors were obtained from resected specimens with a T stage of 1 (n=3) or 2 (n=7) and N
stage of 0 (n=8) or 1 (n=2). More extensive patient data are available in Table S1.
The observed mutations fell in both the extracellular and kinase domains of FGFR2 and
FGFR3, both in codons in which mutations have been previously reported in endometrial
carcinoma (10, 11) and urothelial carcinoma (12), and at novel residues (Figure 1A). In the
samples containing FGFR2 or FGFR3 mutations, the IIIb isoforms of each protein were
overexpressed compared to the IIIc isoforms (Figure S1). FGFR kinase alterations were
significantly enriched in the basal expression subtype (27) (Fisher’s Exact test; p=0.016,
Figure S1).
FGFR mutations co-occurred with mutations in known oncogenes in only three cases.
LUSC-21-1078 had a high somatic mutation rate and harbored mutations in HRAS at codon
61 and PDGFRA at codon 842, both previously reported to be sites of oncogenic mutation,
as well as a novel ERBB2 E1021Q mutation (Figure 1B). LUSC-21-1078 contained a non-
canonical KRAS mutation G118S and LUSC-21-5485 had a previously unreported ERBB2
mutation G1075V. Other samples contained no known oncogenic somatic mutations, except
that FGFR2 and FGFR3 mutations commonly co-occurred with mutations in TP53 (8/10)
and PIK3CA (3/10), the latter a gene with mutations that commonly co-occur with driving
oncogenes. Four of ten samples with FGFR mutation harbored 3q amplification of SOX2
and two samples CDKN2A homozygous deletion (Figure 1B). The presence of these events
may suggest that FGFR mutations are not solely driving oncogenesis; however, due to the
high heterogeneity observed in the lung SqCC samples, even the presence of other known
oncogenic events does not guarantee that events co-occur in cells or that subsets of tumor
cells would not be sensitive to FGFR targeted therapy.
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FGFR2 and FGFR3 mutations drive anchorage-independent growth of NIH-3T3 cells
To determine whether the mutations identified in lung SqCC were oncogenic, we established
NIH-3T3 cells stably expressing each mutation to assess anchorage-independent growth in
soft agar. We observed colony formation in cells expressing the majority of observed
FGFR2 and FGFR3 mutations (Figure 2A). We determined that extracellular domain
mutations W290C and S320C in FGFR2, and R248C and S249C in FGFR3, significantly
increased colony formation compared to wild type FGFR2 or FGFR3, as did kinase domain
mutations K660E and K660N in FGFR2 (p<0.05 by Student’s t-test). In contrast, FGFR2
mutations E471Q and T787K, and FGFR3 mutations S435C and K717M did not form
colonies above wild type. Robust formation of colonies was observed in NIH-3T3 cells
expressing an activating EGFR insertion mutation. FGFR2 mutations were generated in both
common isoforms of FGFR2 with similar results obtained for all assayed mutations with the
exception of FGFR2 T787K, which was very modestly transforming only in isoform IIIc
(Figure 2A).
FGFR2 and FGFR3 mutations drive tumor formation in xenograft models
NIH-3T3 cells expressing transforming FGFR2 mutations or wild type were injected into
nude mice. Tumors reached approximately 200–300 mm3 in all mice injected with mutant
cells by day 13 and began treatment with a pan-FGFR inhibitor, BGJ398 (28), or vehicle,
with ECD mutations driving particularly strong tumor formation (Figure 2B, solid lines).
Tumors formed by cells expressing wild type FGFR2 grew more slowly, and began
treatment on day 16 (Figure 2B).
Tumors treated with BGJ398 slowed or reversed their growth compared to vehicle (Figure
2B, dashed lines), so that by the end of the study, tumor burden in vehicle-treated versus
BGJ398-treated mice was noticeably distinct (Figure 2C, Figure S2).
Extracellular domain mutations form ligand sensitive intermolecular disulfide bonds
A common mechanism of activation of the FGFR2 and FGFR3 kinases is through the
formation of covalently bound receptor dimers (29, 30). While wild type RTKs maintain
extracellular structure required for ligand binding and receptor dimerization through
intramolecular disulfide bonds, mutant receptors can form intermolecular disulfide dimers
due through a novel cysteine residue created by the mutation itself, or through instability
created by a mutated residue near a structural intramolecular disulfide bond (29). This
mechanism was previously established for FGFR3 mutations that we have observed in lung
SqCC, R248C and S249C (30).
To assess whether mutations in the extracellular domain of FGFR2 and FGFR3 lead to
covalent dimerization, and whether dimerization could be increased by ligand stimulation,
we serum starved cells in the presence of PBS or 5 nM FGF1 and 2 μg/mL heparin for eight
hours, or 5 nM FGF1 and 2 μg/mL heparin for 30 minutes, followed by washing with PBS
and serum starving in the presence of PBS for the remaining 7.5 hours followed by
electrophoresis in both reducing and non-reducing conditions. FGFR2 ECD mutations were
sufficient to drive covalent dimerization in the absence of ligand, but dimerization was
increased in the presence of even 30 minutes of ligand stimulation (Figure S3A). In FGFR3
mutations, on the other hand, dimerization was observed but not increased under ligand-
stimulation conditions (Figure S3B). As has been demonstrated previously (31), FGFR
proteins typically form highly glycosylated folded protein products. While FGFR2 W290C
appears to undergo a glycosylation defect contributing to its lower molecular weight, this
mutant form still retains the capacity to dimerize.
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We then seeded the same cells into soft agar in the presence of PBS, 2 μg/mL heparin alone,
or 5 nM FGF1 and 2 μg/mL heparin. After three weeks, we observed greater colony
formation in response to FGF1 and heparin treatment than in heparin alone or PBS treated
cells (Figure S3C).
FGFR2 and FGFR3-driven cellular transformation is blocked by clinically relevant FGFR
inhibitors
Having established that FGFR2 and FGFR3 mutations in lung SqCC drive anchorage-
independent growth in NIH-3T3 cells, we asked whether this transformation could be
blocked by small molecule inhibitors of FGFRs. NIH-3T3 cells were seeded into soft agar in
the presence or absence of the multi-kinase inhibitor AP24534 (ponatinib), which targets
imatinib-resistant BCR-ABL (32), and has activity against FGFR family members (33).
Colony formation was inhibited in the presence of ponatinib in cells harboring activating
FGFR2 or FGFR3 mutations, but not in cells harboring an activating EGFR insertion
(Figure 3A, left panel). All extracellular domain mutations in FGFR2 and S249C in FGFR3
lost colony forming potential when exposed to 100 nM of drug, whereas kinase domain
mutations lost colony forming potential at 10 nM of drug. Exceptions were FGFR2 K660E
expressed in the IIIc isoform, which behaved similarly to the FGFR2 ECD mutations, and
FGFR3 R248C, which had a ten-fold higher inhibitory concentration than any other
mutation, at 1 μM. Colony formation driven by EGFR was not lost until cells were exposed
to 10 μM of drug.
To determine whether ponatinib was inhibiting colony formation driven by mutant FGFR2
and FGFR3, we assessed phosphorylation of several proteins in the FGFR signaling
pathway. Levels of phospho-FGFR, phospho-FRS2, and phospho-Erk all decreased in
response to increasing concentrations of ponatinib (Figure 3B), suggesting that colony
formation was lost due to a decrease in FGFR-mediated signaling.
To evaluate whether ponatinib was acting by specific inhibition of FGFR kinases, these
assays were also performed with BGJ398, a selective FGFR kinase inhibitor (28) as well as
pazopanib (GW786034) (34) and dovitinib (TKI-258) (35), two multi-kinase inhibitors with
specificity for FGFR family members. Colony formation was inhibited by at least 50% in
the presence of 10 nM BGJ398 for all cells expressing FGFR mutations, while cells
expressing the activating EGFR insertion did not lose the capacity for colony formation until
1 μM BGJ398 (Figure 3A, right panel), and wild type phosphorylation was lost at 10 nM
under ligand stimulation conditions (Figure S4A). Dovitinib also inhibited colony formation
in cells expressing mutant FGFR compared to activated EGFR, but with less uniformity
across mutations. FGFR2 ECD mutations lost 50% colony formation between 100 nM and 1
μM dovitinib. In contrast, colony formation was inhibited by 50% between 10 nM and 100
nM for FGFR2 kinase domain mutations excluding K660E IIIc, which behaved similarly to
the FGFR2 ECD mutations. Cells expressing FGFR3 R248C and S249C were sensitive
between 10 nM and 100 nM. Again, cells transformed by mutant EGFR did not lose colony
formation until exposed to 10 μM drug (Figure S4B, left panel). Mutant EGFR-expressing
cells had sustained phosphorylation at AKT T308 up to 10 μM dovitinib, as detected by
immunoblot, while detectable AKT phosphorylation was lost by 100 nM to 1 μM dovitinib
in cells expressing FGFR mutations (Figure S4C). Pazopanib similarly inhibited colony
formation in cells expressing all FGFR2 and FGFR3 mutations at concentrations of 100
nM-1 μM drug, while cells expressing mutant EGFR formed colonies even in the presence
of 10 μM drug (Figure S4B, right panel). Consistently, biochemical studies revealed
sustained AKT T308 phosphorylation in mutant EGFR cells exposed to 10 μM pazopanib,
while detectable AKT T308 phosphorylation was lost in mutant FGFR cells at 100 nM to 1
μM pazopanib (Figure S4D).
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In NIH-3T3 cells expressing the extracellular domain mutations of both FGFR2 and FGFR3
and in the kinase domain mutation FGFR2 K660E IIIc, we observed that low concentrations
of ponatinib (10 nM) conferred a growth promoting phenotype above control, which was
abrogated at higher concentrations (Figure 3A, left panel). This could be due to the multi-
kinase inhibitory properties of ponatinib, which may inhibit a second kinase that could
impact FGFR2 or FGFR3 signaling. This phenomenon was also observed when these
experiments were performed with the two other multi-kinase inhibitors with anti-FGFR
activity, pazopanib and dovitinib (Figure S4B), but not with BGJ398, a more selective
FGFR kinase inhibitor (Figure 3A, right panel).
Analysis of FGFR2 and FGFR3 inhibition in IL-3 independent Ba/F3 cells
To test whether cellular transformation driven by mutated FGFR2 could be abrogated in a
second system by small molecule FGFR inhibitors and to test the relative efficacy of these
compounds, we generated Ba/F3 cells expressing the FGFR2 mutations that had
demonstrated significant colony formation in the NIH-3T3 anchorage-independence assay.
These cell lines were dependent on FGFR signaling in the presence of FGF and heparin, and
in the absence of IL-3. Phosphorylation of the FGFR kinase domain and FRS2 were
measured by immunoblot, and interestingly, cells expressing FGFR2 K660E IIIc showed a
greater degree of phosphorylation of both molecules despite similar expression levels as
compared to cells expressing other mutations (Figure 4A).
Ba/F3 cells expressing wild-type and mutated FGFR2 transgenes were first seeded into
media containing increasing concentrations of ponatinib. We observed that ponatinib
inhibited IL-3 independent proliferation of Ba/F3 cells expressing the FGFR mutations at
about 10 nM of drug treatment, but cells expressing an EGFR activating insertion or parental
Ba/F3 cells grown in the presence of IL-3 were only inhibited by 10 μM of drug (Figure 4B,
left panel). IC50 values for Ba/F3 cells expressing each mutant were also calculated and
plotted (Figure 4C, left panel). These assays were also performed on cells seeded into media
containing BGJ398, and similarly, cells expressing FGFR mutations, but not the EGFR
insertion or parental Ba/F3 cells, were inhibited at about 10 nM inhibitory concentrations of
drug (Figure 4B, right panel and Figure 4C, right panel). Interestingly, insensitive controls in
the presence of ponatinib appeared to gain a growth advantage in the presence of drug at
concentrations in the range of 10–100 nM (Figure 4B), similar to our observations in the
anchorage independence colony formation assay (Figure 3A, Figure S4B).
To further assess the potency of small molecule FGFR kinase inhibitors in the Ba/F3 system,
we assembled a panel of FGFR kinase inhibitors described in the literature ((28, 32–39),
Table S2) and tested the Ba/F3 inhibitory response in the presence of each. Each of these
inhibitors demonstrated similar trends to those seen for ponatinib and BGJ398: a multi-log
increase in drug sensitivity in cells expressing FGFR mutations compared to controls
(Figure S5). IC50 values for each mutation in the presence of each drug were also calculated
(Figure S5). Strikingly, FGFR2 K660E expressed in the IIIc isoform (in yellow) repeatedly
exhibited a 5–10 fold higher IC50 concentration as compared to the IIIb isoform and either
isoform of the K660N mutation in the FGFR2 kinase domain (Figure S5). This observation
was consistent with the concentrations at which anchorage independent growth observed for
FGFR2 K660E IIIc was lost in the presence of several inhibitors (Figure 3A and Figure
S4B).
Case report of a head and neck SqCC patient responding to an FGFR inhibitor
We identified an individual with squamous cell carcinoma of the head and neck who was
found to harbor an extracellular FGFR2 mutation (p.P253R) in a biopsy specimen (Figure
5A). This mutation was initially identified in RNA sequencing data and then confirmed by
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Sanger sequencing in a CLIA-certified laboratory (Figure 5B). FGFR2 mutations have
previously been observed at low frequencies in head and neck cancer (40, 41), and
confirmed by initial reports from TCGA where seven mutations were observed in exome
sequencing data of 279 individuals as of October 1, 2012 (data obtained from the TCGA
Data Coordinating Center). FGFR2 P253R has previously been observed in endometrial
carcinoma (10). Cellular and biochemical analysis of the FGFR2 P253R mutation suggest
that this event is transforming and sensitive to targeted therapies in our assays, similar to the
events observed in lung SqCC (Figure S6).
The patient was diagnosed with locally advanced (T2N1M0, stage III) squamous cell
carcinoma of the right tongue in 2008 at the age of 52. He had no history of tobacco use or
alcohol abuse and was treated with a right hemiglossectomy and post-operative radiation
therapy. He subsequently developed recurrences in the right and left neck over a period of
three years and was treated with surgery, two additional courses of radiation therapy and
multiple courses of chemotherapy including carboplatin, paclitaxel, cisplatin and cetuximab.
In 2012, he had further progression in the right neck and left axilla. He began daily
treatment with 800 mg pazopanib starting on April 12, 2012. At this time, he had gross
disease in the right neck (Figure 5C, left panels). A follow up visit 12 days later showed a
marked reduction in tumor size (Figure 5C, right panel). He continued on pazopanib for two
months, when he presented with a right carotid hemorrhage. Pazopanib was discontinued at
that time, and the patient remains alive as of March 15, 2013 under hospice care. This
correlative observation does not definitively identify FGFR2 as the target of pazopanib, but
we believe that this result provides compelling rationale to continue to pursue treatment of
FGFR2-mutated tumors with anti-FGFR targeted therapies.
Discussion
Lung squamous cell carcinoma is a poorly characterized disease responsible for 40,000 new
deaths per year in the US. One of the most provocative findings from genomic analysis is
that of recurrent FGFR2 and FGFR3 mutations, which are significant given that germline
FGFR mutations are known to be pathogenic (17), that somatic mutations have been
described in other malignancies (18), and that focal FGFR1 amplification is known to occur
in lung SqCC and appears to be a therapeutic target (15, 16).
We have confirmed that a subset of observed mutations drive transformation in NIH-3T3
cells in an anchorage independent growth assay and xenograft assays, and that this is
reversible by pan-FGFR and multi-kinase inhibitors. Some mutations were not transforming,
but given the very high somatic mutation rate in lung SqCC, this observation is not
surprising. We found that extracellular domain mutations in FGFR2 are able to form ligand
sensitive covalent receptor-dimers, as has been observed in other FGFR2 ECD mutations
(29) and in FGFR3 mutations that have been described previously in urothelial carcinoma,
and which we also observe here in the lung SqCC data (30). This finding is especially
relevant given that the FGFR2 W290C mutation has been observed independently in lung
SqCC sequencing on two previous occasions (10, 42). It is also possible that the
glycosylation deficiency that we observed in the expressed protein harboring this mutation
impacts protein function, a phenomenon with precedence in this receptor family (31).
We found that the FGFR mutations also exhibited sensitivity to inhibition by FGFR
inhibitors in the Ba/F3 system, which models dependency on oncogenic pathways. Many
drugs in the panel of inhibitors that we tested are already approved for clinical use in other
malignancies, and clinical trials are underway to test sensitivity to FGFR inhibitors in
patients harboring FGFR events (NCT01004224, NCT01457846, NCT00979134). While we
cannot infer in vivo sensitivity to these inhibitors from our models, we believe that this
Liao et al. Page 9













study provides a compelling rationale for extending trials of FGFR kinase inhibitors to
patients with lung and oral SqCC harboring FGFR2 or FGFR3 mutations.
This study represents one of the first functionally validated novel recurrent targets to emerge
from analysis of the systematic genomic profiling of lung SqCC by the TCGA Research
Network. It is our expectation that these findings will continue with the publication of more
genomic studies of malignancies, and that this will lead to improved treatment options for
patients with this disease.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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FGFR2 and FGFR3 mutations, each found in 3% of lung squamous cell carcinomas,
drive cellular transformation and are associated with response to FGFR kinase inhibitors
currently in clinical development. These findings provide a rationale for therapeutic
targeting of FGFR2 and FGFR3 mutations in lung and head and neck squamous cell
carcinoma.
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Recurrent mutations in FGFR2 and FGFR3 are observed in lung squamous cell carcinoma.
(A) Sequencing data from TCGA were analyzed and recurrent mutations were observed in
FGFR2 and FGFR3. The mutation S320C in FGFR2, in red, is located in the alternatively
spliced exon in the IG-3 domain of FGFR2 IIIb; the remaining mutations are annotated to
the IIIc isoform. FGFR3 mutations are annotated in the IIIc isoform. (B) Co-occurring
somatic copy number alterations and mutations in samples with mutation.
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A subset of lung SqCC mutations in FGFR2 and FGFR3 are transforming in anchorage
independent growth assays and xenograft assays. (A) Colony formation compared to wild
type in NIH-3T3 cells expressing FGFR mutations was calculated for each isoform and
graphed. EGFR insNPG was included as a positive control, and the pBabe-puro Gateway
empty vector (pBp GW) was included as a negative control. P-values were calculated with
the student’s t-test and significance is indicated by asterisks; * < 0.05, ** < 0.01, *** <
0.001. (B) Nude mice injected with transforming FGFR2 mutant cells from (A) developed
tumors, which were treated with BGJ398 (dashed lines) or vehicle (solid lines). (C) Tumors
were dissected from the mice for visual inspection comparing treatment with vehicle or
drug. Top panel, FGFR2-W290C tumors; bottom panel, FGFR2-S320C. Tumor images
corresponding to FGFR2-K660N and FGFR2-WT tumors are shown in Figure S2.
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Anchorage independent colony formation is abrogated in the presence of anti-FGFR
inhibitors. (A) NIH-3T3 cells expressing each transforming mutation were seeded in the
presence of increasing concentrations of ponatinib (AP24534) (left panel) and BJG398 (right
panel). (B) Cells were serum starved and exposed to the indicated concentrations of
ponatinib for four hours and then ligand stimulated for 30 minutes with FGF1, after which
cells were lysed and probed via immunoblot. These experiments were performed with
several other clinical inhibitors; those results are documented in Figure S4.
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Ba/F3 cells dependent on FGFR signaling are sensitive to FGFR inhibitors. (A) Ba/F3 cells
dependent on FGFR signaling were isolated by exchanging IL-3 with FGF-7 or FGF-9 and
heparin. These cells were lysed and probed for FGFR2 or FGFR3 expression, phospho-
FGFR, FRS2, and phospho-FRS2 Y436. Actin was used as a loading control. (B) Ba/F3
cells expressing each mutation construct were seeded into 96-well plates, in the presence of
increasing concentrations of ponatinib (left panel) or BGJ398 (right panel). After four days,
proliferation was measured with Cell Titer Glo. (C) IC50 values were calculated for each
mutation. These experiments were performed with other FGFR inhibitors; those results are
documented Figure S5.
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An oral squamous cell carcinoma patient harboring a somatic FGFR2 P253R mutation
demonstrates a partial response to an FGFR inhibitor. (A) A schematic shows the P253R
mutation in the FGFR2 extracellular domain. (B) mRNA sequencing was performed and a
somatic mutation in FGFR2 was identified, shown in the IGV viewer. (C) Pre- and post-
treatment images from the patient.
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